Argenica Therapeutics Ltd has released a press release.
ARG-007 Protects Brain Cells in Moderate TBI Model
Filed with ASX ·
6ix hasn’t read this filing yet.
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Argenica Successfully Completes $4.0m Placement
- Final Phase1 Clinical Trial Report
- Latest Preclinical HIE Study Results
- Significant Non-Dilutive Funding For Preclinical HIE Studies
- Interim Phase 1 Safety Report Confirms Safety of ARG-007
Later from Argenica Therapeutics
- ARG-007 Phase 2 Clinical Trial Update
- Investor Presentation
- ARG-007 Prevents Uptake & Aggregation of Key Protein
- Response to ASX Aware Query
- Appendix 4E & Annual Report 30 June 2023
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics